Study of How People Make Decisions About Prostate Cancer Risk
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age45-70
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Eligibility criteria
Qualifiers
Documentation of Disease
Age between 45 - 70;
Assigned male sex at birth
Completed full sequence or targeted genetic testing with a result confirmed in a clinically approved laboratory showing a BRCA1/2 likely pathogenic or pathogenic variant identified, or clinician note documents a BRCA1/2 likely pathogenic or pathogenic variant
Disqualifiers
Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
Under active treatment for a malignancy. (Patients are eligible if they have a prior history of malignancy other than prostate cancer, as long as they are not currently undergoing active treatment for the malignancy)
Enrolled in NCI study 19-C-0040 (Natural History of Men at High-Risk for Prostate Cancer) based on self-report
Trial design
Treatments tested in this trial
- cheek (buccal) swab
- Assessments
- optional collection of blood
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
CureBRCA Foundation
Collaborator
Source ClinicalTrials.gov